Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Mindset Pharma Inc. (MSSTF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.3001-0.0003 (-0.11%)
At close: 03:21PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3004
Open0.3000
BidN/A x N/A
AskN/A x N/A
Day's Range0.3000 - 0.3001
52 Week Range0.2335 - 0.7573
Volume6,476
Avg. Volume12,231
Market Cap29.448M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1890
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.99
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MSSTF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MINDSET PHARMA INC
    Daily Spotlight: Important Inflation News Out TodayThe Federal Reserve's favorite inflation indicator, the PCE Price Index, will be released by the BEA today. The PCE Index differs from the better-known Consumer Price Index in that its components are more variable and are quicker to reflect real-time pricing fluctuations. In the most-recent report (from September), PCE inflation was reported at 6.2% (the latest CPI report, from October, had inflation at 7.7%). At Argus, we forecast a rate of 5.9% for the October PCE Price Index. Core PCE, which removes volatile food and energy prices, was 5.1% in the last month. We expect the Core PCE to tick lower to 5.0% this month. Overall, inflation appears to have peaked during the summer and is starting to decline. We track 21 inflation measures on a monthly basis. On average, they are indicating that prices are rising at a 5.2% rate year-over-year, down from 6.8% last month and from 8.7% four months ago. Drilling down to core inflation (which we obtain by averaging Core CPI, market-based PCE Ex-Food & Energy, the core GDP PCE Price Index, the five-year forward inflation expectation rate, and the 10-year TIPs Break-even Interest Rate), our reading is 4.1%. That's down slightly from our 4.3% reading last month. We note some movement among our components. Producer Prices appear to be cooling off, with substantial declines in PPI Intermediate Prices for Processed and Unprocessed Goods. The rate of wage increases also is slowing. Looking down the road, investors are expecting that the Federal Reserve's series of rate hikes ultimately will tame inflation, with the three-year forward expectation rate now down to 3.1% and the five-year forward expectation rate at 2.3%.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Mindset Pharma CEO, James Lanthier Issues Letter to Shareholders

    TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset. Dear Fellow Shareholders: As we approach the end of 2022, I would like to take a moment to remind both shareholders and the broader investment community of Mindset’s recent accomplishments since our last update and express our excitement for 2023 and beyond. Mindset is focus

  • GlobeNewswire

    Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin

    Pharmaceutical Grade Psilocybin Synthesized By Mindset’s Patent Pending ProcessTORONTO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, and PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on th

  • GlobeNewswire

    Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement

    PharmAla will be the exclusive global reseller of Mindset’s cGMP psilocybin to appropriately licensed clinical researchersVANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, and Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset"), a drug discovery company developing novel, optimized, next-gene

Advertisement
Advertisement